SEP 24, 2014 10:00 AM PDT

Keynote, The Promises and Challenges of Next-Generation Therapeutics

Speakers
  • CEO, Warp Drive Bio, Erving Professor of Chemistry, Harvard University
    Biography
      Gregory Verdine is a pioneer in the field of chemical biology, having served as the Erving Professor of Chemistry at Harvard University for the past 25 years. Among many scientific accomplishments, he discovered the molecular mechanism of epigenetic DNA methylation and developed a new class of therapeutics termed stapled peptides, which are currently in clinical development. In addition to Warp Drive, Greg has co-founded multiple biotechnology companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. In 2009, he joined Third Rock Ventures as a venture partner. Verdine holds a Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph's University, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School. His talk will be on the discovery and synthesis of natural product-like compounds.

    Abstract:

    The ever-quickening pace of breathtaking advances in our understanding of disease biology has implicitly promised a profusion of drugs that will dramatically improve human health and well-being. Realization of this promise remains frustratingly elusive. Where are all the new drugs? We contend that a major contributing factor is the limitations in target scope of the two well-establish drug modalities, namely small molecules and protein therapeutics. Addressing this targetability gap will require the discovery and development of entirely new structural classes of drugs and the pioneering of new strategies for finding them. Any fundamentally new class of drug introduces discovery challenges that fall outside the hard-won risk-mitigation paradigms for established classes of drugs, hence the reluctance of pharma, biotech and even the investment community to fully embrace next-generation therapeutic modalties. Learning how to navigate these challenges will therefore fall disproportionately to the academic community, and will not be easy or happen quickly. That said, recent developments in the field of next-generation therapeutics give reason to be cautiously optimistic.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    AUG 13, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 13, 2019 09:00 AM PDT
    DATE: August 13, 2019TIME: 9:00am PT, 12:00pm ET, 5:00pm BST Molecular complexes are major constituents of cells, hence unraveling their mechanisms is key to fuller comprehension of c...
    Loading Comments...
    Show Resources